<br>        Inclusion Criteria:<br><br>          -  Metastatic Castration-Resistant Prostate Cancer Progression after one or two prior<br>             cytotoxic chemotherapies<br><br>          -  At least one chemotherapy must have contained docetaxel<br><br>          -  Eastern Cooperative Oncology Group (ECOG) Performance Status <= 2<br><br>          -  Medical or surgical castration with testosterone < 50 ng/dL<br><br>          -  Adequate bone marrow, hepatic and renal function<br><br>          -  Potassium >= 3.5 mmol/L<br><br>          -  Able to swallow the study drug whole as a tablet<br><br>          -  Informed Consent<br><br>        Exclusion Criteria:<br><br>          -  More than two prior cytotoxic chemotherapy regimens<br><br>          -  Prior Ketoconazole for prostate cancer<br><br>          -  Prior abiraterone acetate or other CYP17 inhibitor or investigational agents targeting<br>             the androgen receptor for prostate cancer<br><br>          -  Uncontrolled hypertension<br><br>          -  Active or symptomatic viral hepatitis or chronic liver disease<br><br>          -  History of pituitary or adrenal dysfunction<br><br>          -  Clinically significant heart disease<br><br>          -  Other malignancy<br><br>          -  Known brain metastasis<br><br>          -  GI disorder affecting absorption<br><br>          -  Not willing to use contraception<br>      ;<br>        Inclusion Criteria:<br><br>          -  Metastatic Castration-Resistant Prostate Cancer Progression after one or two prior<br>             cytotoxic chemotherapies<br><br>          -  At least one chemotherapy must have contained docetaxel<br><br>          -  Eastern Cooperative Oncology Group (ECOG) Performance Status <= 2<br><br>          -  Medical or surgical castration with testosterone < 50 ng/dL<br><br>          -  Adequate bone marrow, hepatic and renal function<br><br>          -  Potassium >= 3.5 mmol/L<br><br>          -  Able to swallow the study drug whole as a tablet<br><br>          -  Informed Consent<br><br>        Exclusion Criteria:<br><br>          -  More than two prior cytotoxic chemotherapy regimens<br><br>          -  Prior Ketoconazole for prostate cancer<br><br>          -  Prior abiraterone acetate or other CYP17 inhibitor or investigational agents targeting<br>             the androgen receptor for prostate cancer<br><br>          -  Uncontrolled hypertension<br><br>          -  Active or symptomatic viral hepatitis or chronic liver disease<br><br>          -  History of pituitary or adrenal dysfunction<br><br>          -  Clinically significant heart disease<br><br>          -  Other malignancy<br><br>          -  Known brain metastasis<br><br>          -  GI disorder affecting absorption<br><br>          -  Not willing to use contraception<br>      ;<br>        Inclusion Criteria:<br><br>          -  Metastatic Castration-Resistant Prostate Cancer Progression after one or two prior<br>             cytotoxic chemotherapies<br><br>          -  At least one chemotherapy must have contained docetaxel<br><br>          -  Eastern Cooperative Oncology Group (ECOG) Performance Status <= 2<br><br>          -  Medical or surgical castration with testosterone < 50 ng/dL<br><br>          -  Adequate bone marrow, hepatic and renal function<br><br>          -  Potassium >= 3.5 mmol/L<br><br>          -  Able to swallow the study drug whole as a tablet<br><br>          -  Informed Consent<br><br>        Exclusion Criteria:<br><br>          -  More than two prior cytotoxic chemotherapy regimens<br><br>          -  Prior Ketoconazole for prostate cancer<br><br>          -  Prior abiraterone acetate or other CYP17 inhibitor or investigational agents targeting<br>             the androgen receptor for prostate cancer<br><br>          -  Uncontrolled hypertension<br><br>          -  Active or symptomatic viral hepatitis or chronic liver disease<br><br>          -  History of pituitary or adrenal dysfunction<br><br>          -  Clinically significant heart disease<br><br>          -  Other malignancy<br><br>          -  Known brain metastasis<br><br>          -  GI disorder affecting absorption<br><br>          -  Not willing to use contraception<br>      ;<br>        Inclusion Criteria:<br><br>          -  Metastatic Castration-Resistant Prostate Cancer Progression after one or two prior<br>             cytotoxic chemotherapies<br><br>          -  At least one chemotherapy must have contained docetaxel<br><br>          -  Eastern Cooperative Oncology Group (ECOG) Performance Status <= 2<br><br>          -  Medical or surgical castration with testosterone < 50 ng/dL<br><br>          -  Adequate bone marrow, hepatic and renal function<br><br>          -  Potassium >= 3.5 mmol/L<br><br>          -  Able to swallow the study drug whole as a tablet<br><br>          -  Informed Consent<br><br>        Exclusion Criteria:<br><br>          -  More than two prior cytotoxic chemotherapy regimens<br><br>          -  Prior Ketoconazole for prostate cancer<br><br>          -  Prior abiraterone acetate or other CYP17 inhibitor or investigational agents targeting<br>             the androgen receptor for prostate cancer<br><br>          -  Uncontrolled hypertension<br><br>          -  Active or symptomatic viral hepatitis or chronic liver disease<br><br>          -  History of pituitary or adrenal dysfunction<br><br>          -  Clinically significant heart disease<br><br>          -  Other malignancy<br><br>          -  Known brain metastasis<br><br>          -  GI disorder affecting absorption<br><br>          -  Not willing to use contraception<br>